

1

SEQUENCE LISTING

<110> CTT Cancer Targeting Technologies Oy

<120> Method for designing peptides

<130> 41640

<140>

<141>

<160>

<170> PatentIn Ver. 2.1

<210> 1

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
CTT2-peptide

<400> 1

Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu
1 5 10 15

Cys

<210> 2

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Lys-substitution of the CTT2-peptide

<400> 2

Lys Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu
1 5 10 15

Cys

<210> 3

<211> 18

<212> PRT

<213> Artificial Sequence

2

<220>

<223> Description of Artificial Sequence:
CTT2-peptide with additional Lys

<400> 3

Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu
1 5 10 15

Cys Lys

<210> 4

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
CTT2-peptide with a tryptophan analogue at position 12

<220>

<221> SITE

<222> (5)

<223> Xaa at position 12 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

<400> 4

Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Xaa Gly Phe Thr Leu
1 5 10 15

Cys